Mode
Text Size
Log in / Sign up

Meta-analysis finds virtual reality exposure therapy reduces anxiety and PTSD symptoms

Meta-analysis finds virtual reality exposure therapy reduces anxiety and PTSD symptoms
Photo by Bermix Studio / Unsplash
Key Takeaway
Consider VRET as a potential exposure tool for anxiety and PTSD, but note evidence gaps on safety and comparators.

This meta-analysis pooled data from 26 randomized controlled trials involving 1,649 patients diagnosed with anxiety-related disorders and posttraumatic stress disorder (PTSD). The intervention studied was virtual reality exposure therapy (VRET). The specific comparator treatments used in the individual trials were not reported.

The analysis found VRET was associated with significant reductions in several symptom domains. For phobia symptoms, the pooled effect size was Hedges' g = -0.98 (95% CI = -1.37, -0.60, P < 0.001). For anxiety symptoms, the effect size was Hedges' g = -0.61 (95% CI = -0.90, -0.33, P < 0.001). For PTSD symptoms, the effect size was Hedges' g = -0.51 (95% CI = -0.72, -0.30, P < 0.001). VRET was also associated with increased approach behavior (Hedges' g = 0.62, 95% CI = 0.11, 1.12, P = 0.02). Absolute numbers or event rates for these outcomes were not reported.

No data on adverse events, serious adverse events, discontinuations, or tolerability were reported. Key limitations of the evidence were not detailed in the provided summary. The authors describe VRET as a valuable exposure-based treatment tool due to its immersive features but state further randomized controlled trials using advanced technologies and standardized protocols are needed to strengthen the evidence base. The analysis reports associations from RCTs but does not establish definitive causation.

Study Details

Study typeMeta analysis
Sample sizen = 1,649
EvidenceLevel 1
PublishedMar 2026
View Original Abstract ↓
BACKGROUND: Anxiety disorders impose a substantial burden on individuals and society, affecting mental health, quality of life, and health care systems. Virtual reality exposure therapy (VRET) has emerged as a promising treatment. However, existing meta-analyses often included participants without clinically diagnosed anxiety or related disorders. This study aimed to evaluate the efficacy of VRET in reducing anxiety, phobia, behavioural symptoms, and posttraumatic stress disorder (PTSD) among patients with anxiety-related disorders and PTSD. METHODS: A systematic search was conducted across seven databases - CINAHL, Embase, PubMed, PsycINFO, Web of Science, Cochrane Library, and Medline-OVID. Eligible studies included randomised controlled trials (RCTs) examining the effects of VRET on anxiety-related outcomes. Data were pooled using a random-effects model with Comprehensive Meta-Analysis (version 3.0; Biostat, Englewood, NJ, USA). Effect size were calculated using Hedges' g, and moderator analyses explored potential factors influencing the effect sizes. RESULTS: Twenty-six RCTs involving 1649 participants met the inclusion criteria. Overall, VRET demonstrated significant and clinically meaningful effects across multiple domains. It reduced phobia symptoms (Hedges' g = -0.98; 95% confidence interval (CI) = -1.37, -0.60, P < 0.001), increased approach behaviour (Hedges' g = 0.62; 95% CI = 0.11, 1.12, P = 0.02), alleviated anxiety symptoms (Hedges' g = -0.61; 95% CI = -0.90, -0.33, P < 0.001), and mitigated PTSD symptoms (Hedges' g = -0.51; 95% CI = -0.72, -0.30, P < 0.001). Moderator analyses indicated that shorter intervention durations (<60 minutes) were associated with larger treatment effects on anxiety and phobia. VR-based Cognitive Behavioral Therapy (VR-CBT) and VRET demonstrated large and significant effects for phobia. CONCLUSIONS: VRET effectively reduces anxiety, phobia, and PTSD symptoms while enhancing approach behaviour in clinically diagnosed patients. Its immersive and adaptable features make it a valuable exposure-based treatment tool. Further RCTs using advanced VR technologies and standardised protocols are needed to strengthen the evidence and optimise clinical application. REGISTRATION: Open Science Framework (https://doi.org/10.17605/OSF.IO/AD4M2).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.